Skip to main content
Ascentage Pharma Group International logo

Ascentage Pharma Group International — Investor Relations & Filings

Ticker · 6855 HKEX Manufacturing
Open in API
Filings indexed 401 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6855

About Ascentage Pharma Group International

https://www.ascentage.cn

Ascentage Pharma Group International is a global, integrated biopharmaceutical company dedicated to discovering, developing, and commercializing novel small molecule therapies with first-in-class or best-in-class potential. The company primarily targets unmet medical needs in cancers, chronic hepatitis B virus (HBV), and age-related diseases. Its core scientific strategy focuses on restoring intrinsic apoptogenic forces (programmed cell death) in cancer cells. Key commercialized and late-stage assets include the third-generation BCR-ABL inhibitor Olverembatinib and the novel Bcl-2 inhibitor Lisaftoclax (APG-2575). Ascentage maintains a robust global clinical development program, conducting over 40 trials across multiple continents, supported by numerous US FDA and EU Orphan Drug Designations and strategic partnerships with leading pharmaceutical and academic institutions worldwide.

Recent filings

Filing Released Lang Actions
SECOND FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 20, 2026
Regulatory Filings
2026-04-30 English
SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING
Regulatory Filings
2026-04-30 English
SUPPLEMENTAL CIRCULAR - PROPOSED GRANTS UNDER THE 2022 RSU SCHEME AND POST-IPO SHARE OPTION SCHEME TO DR. YANG AND DR. ZHAI; AND SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING
Regulatory Filings
2026-04-30 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 20, 2026
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a "Form of Proxy" for the Annual General Meeting of Ascentage Pharma Group International, providing shareholders with voting instructions and appointing proxies. This is not the AGM presentation itself nor a simple notice of report publication, but rather the proxy solicitation material sent to shareholders to facilitate voting at the AGM. Therefore, it best fits the "Proxy Solicitation & Information Statement" category (Code: PSI).
2026-04-29 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is the formal Notice of Annual General Meeting of Ascentage Pharma Group International, sent to shareholders to inform them of meeting details, proposed resolutions, and to solicit proxy votes. It is not the AGM presentation itself, nor a financial report or results announcement. It falls under “Proxy Solicitation & Information Statement” as materials requesting shareholder votes at a general meeting.
2026-04-29 English
PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION AND PROPOSED
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a detailed pre‐meeting circular (“THIS CIRCULAR IS IMPORTANT…”) for Ascentage Pharma Group International’s Annual General Meeting, including the notice of meeting, explanatory statements on resolutions (re‐election of directors, share issue and repurchase mandates, amendments to constitutional documents), and proxy form. These materials are sent to shareholders to solicit their votes. This fits the definition of Proxy Solicitation & Information Statement (PSI), not an AGM presentation (AGM‐R) or just a notice of report publication.
2026-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.